FDA clears chemical countermeasure
This article was originally published in The Gray Sheet
Executive Summary
Canada-based O'Dell Engineering is in the process of securing a contract with the U.S. military for the firm's RSDL (Reactive Skin Decontamination Lotion), following FDA clearance March 26 based on a 300-patient trial co-sponsored by the U.S. Marine Corps. RSDL - a sponge impregnated with lotion that "if used in time...can prevent the serious burns and deaths that result from exposure to chemical warfare agents," according to FDA Commissioner Mark McClellan - will be marketed for use by the military and journalists at risk for exposure to chemical weapons. FDA granted RSDL expedited review in January, but had delayed clearance to request further information...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.